Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.86), versus ($0.94) reported last year. Revenue for the quarter came in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE